Artificial Intelligence
Clinical Highlights: 15th Annual CMHC Live Online
Boca Raton, FL, Oct. 29, 2020 (GLOBE NEWSWIRE) — The 15th Annual CMHC Live Online concluded on Saturday, October 24th. For the first time in its history, the event was delivered entirely online to practitioners across the nation. Through an innovative and user-friendly virtual platform participants were able to interact with faculty members, participate in audience polls, and more, all from the setting of their own choosing. Chaired by an esteemed panel of expert faculty members Robert H. Eckel, MD; Christie M. Ballantyne, MD; George L. Bakris, MD; Anne L. Peters, MD; Deepak L. Bhatt, MD, MPH; Keith C. Ferdinand, MD; Clyde W. Yancy, MD, MSc, MACP; and Pamela B. Morris, MD, the conference provided actionable insights on late-breaking research, advanced clinical approaches to cardiometabolic challenges, and practical strategies to tackle inequity in healthcare.
Impact of Ethnicity and Race in Cardiometabolic Health: Implications for Risk Assessment and Management
Despite therapeutic advances, the burden of cardiovascular disease (CVD), diabetes, atherosclerosis, and several cardiometabolic risk factors remains high in certain racial and ethnic minorities, including in African Americans and Latinos. Significant disparities in CVD morbidity and mortality persist, and across several outcomes and risk factors, African Americans have sub-optimal cardiovascular health. This includes a higher burden of coronary heart disease, heart failure, stroke, and traditional CVD risk factors, such as hypertension, diabetes, lipid disorders, and obesity. Additionally, Hispanic adults are more likely than non-Hispanic adults to be diagnosed with diabetes, as well as at a higher risk for significant morbidity and mortality due to diabetes, including progression to end-stage renal disease, visual impairment, and hospitalizations.
These topics were covered extensively during the pre-conference, chaired by Keith C. Ferdinand, MD, a nationally and internationally recognized cardiologist that has dedicated his career to improving patient care in racial and ethnic minorities. During his opening talk, Dr. Ferdinand mentioned that “cardiometabolic and CVD disparities by race/ethnicity, geography, and socioeconomic status exist, are sizeable, multifactorial, persistent, rarely due to genetics, and are unacceptable.”
Participants then engaged in lectures and discussions on issues such as counseling patients living in food deserts, combination medications in racially marginalized groups, navigating healthcare costs, culturally informed treatment strategies, and more. Led by a panel of clinical leaders at the intersection of race and cardiometabolic care, this offering served to help participants build a practical strategy to effectively navigate the pervasive challenges of inequity in healthcare.
Keynote: Evolving Paradigms in Cardiovascular Research and Care: Reflections and Perspectives
The keynote address was delivered by Eugene Braunwald, MD, a world-renowned cardiologist and a pioneer researcher, physician, and educator in cardiovascular medicine, considered by most to be the preeminent cardiologist of our time. During his keynote presentation, Dr. Braunwald overviewed the remarkable progress that has been achieved in preventive cardiology in just the last two decades, highlighting the role of genetics, artificial intelligence and machine learning, and groundbreaking therapeutics, including PCSK9 inhibitors and SGLT-2 inhibitors. In reviewing the initially surprising results with SGLT-2 inhibitors in cardiorenal risk, he mentioned that they have contributed to three significant paradigm shifts: they provide effective management of cardiac and renal dysfunction in patients with type 2 diabetes, improve the management of heart failure with reduced ejection fraction in patients without diabetes, and are renoprotective in patients with chronic kidney disease with and without type 2 diabetes. Dr. Braunwald concluded that care for patients with cardiovascular disease or risk has been greatly improved due to these advances, and highlighted that much still remains to be done going forward.
Hypertension, Chronic Kidney Disease, and Heart Failure Management
Kicking off the session, CMHC Chair George Bakris, MD discussed how to understand signals from the kidney when blood pressure is rapidly and aggressively controlled. In the setting of controlled blood pressure, or when BP numbers are at goal, interpretation of kidney function, including the estimated glomerular filtration rate (eGFR), albuminuria, creatinine, and potassium levels, is really important to understand in order to decrease overall cardio-renal risk, Dr. Bakris mentioned during his talk. The very important (but often neglected) role of sleep disorders in hypertension was reviewed by Virend Somers, MD, Professor at the Mayo Clinic—who gave the audience practical tips on the association of sleep disorders and hypertension, and how adequate sleeping patterns can improve blood pressure. Dr. Somers concluded by inviting the audience to participate in a CMHC masterclass focused entirely on these issues, “The Intersection of Cardiometabolic Health and Sleep Disorders”, taking place live online on March 27, 2021.
During the primetime symposium “Tackling Diabetic Kidney Disease Progression: Challenges, Advances, and Novel Approaches” experts Rajiv Agarwal, MD, George Bakris, MD, and Janet McGill, MD, discussed the underlying pathophysiology of DKD, how to identify patients at-risk for DKD progression, and the emerging role of non-steroidal mineralocorticoid receptor antagonists (MRAs) in DKD treatment. Clyde Yancy, MD, CMHC’s Senior Planning Committee member and Professor of Medicine at Northwestern University in Chicago, overviewed the landscape with transthyretin cardiac amyloydosis (ATTR-CM). Dr. Yancy mentioned that ATTR-CM is an underestimated cause of heart failure, and that low awareness and limited therapeutic options are significant barriers to optimal care. However, he mentioned, several therapies have been approved or are in clinical development for ATTR-CM and this condition is becoming more relevant to the practice of cardiology. The day concluded with a series of challenging cardio-renal cases to put into perspective these advances.
Dyslipidemia, Atherosclerosis, and Thrombosis
The evolving lipid targets and residual ASCVD risk beyond LDL-C was a significant focus of this session, chaired by CMHC Chair Christie Ballantyne, MD. In his talk “Beyond LDL-C: targeting inflammation to reduce cardiovascular risk”, Paul M. Ridker, MD, MPH, Professor of Medicine at the Harvard Medical School, mentioned the important role of inflammation in the development, progression, and prognosis of atherosclerosis. Patrick Moriarty, MD, Professor of Internal Medicine at the University of Kansas Medical Center in Kansas City, Kansas, overviewed the role of elevated lipoprotein a, Lp(a), and concluded that it is an independent risk factor for ASCVD that deserves appropriate screening and treatment.
The primetime symposium, “The Evolving Landscape of LDL-C Reduction: Novel Therapies and Approaches”, with Christie Ballantyne, MD, Salim Virani, MD, and Pam Taub, MD, discussed clinical inertia with LDL-C lowering, current guidelines, and the evidence and role for newer and emerging agents, including bempedoic acid and inclisiran, in addressing current gaps and needs with LDL-C lowering. The session concluded with a panel discussion of challenging cases, including severe hypertriglyceridemia, residual ASCVD risk & inflammation, elevated Lp(a), and complex primary ASCVD prevention.
Diabetes Management
C. Ronald Kahn, MD, Professor of Medicine at Harvard Medical School in Boston, MA, and prominent physician-researcher, kicked off the session with his talk titled “Insulin resistance: a 2020 update.” In his talk, Dr. Kahn mentioned that Insulin resistance is a key factor that underlines obesity, type 2 diabetes, and overall cardiometabolic risk, and concluded that “understanding what creates this multi-dimensional signaling defect should define a new approach to the therapy of type 2 diabetes.”
The primetime symposium “Preventing Cardiovascular Events in High-Risk Diabetes Patients with CAD: New Insights and Developments” explored unique issues in antithrombotic and antiplatelet therapy in diabetes patients, a key component to reduce the risk of adverse events. During this symposium, Deepak Bhatt, MD, Lawrence Leiter, MD, and Prof. Philippe Steg discussed the role of more aggressive and specific antithrombotic agents in this setting, as outlined by recent clinical trials, as well illustrated these advanced with the help of a complex patient case that took into account how to optimize lipid, glycemic, and antithrombotic and antiplatelet therapy in patients with type 2 diabetes. The session continued with a talk by Kathleen Dungan, MD, Associate Professor of Medicine at the Ohio State University in Columbus, OH, which explored new emerging therapies in the management of type 2 diabetes. One of the emerging approaches, Dr. Dungan mentioned, is the development of dual and triple peptide agents, including GLP-1/GIP agonists, novel GIP agonists, GLP-1/glucagon receptor dual agonists, and GLP-1/GIP/glucagon triagonists. In conclusion, she mentioned that “combination therapy has the potential to improve glycemic control, can overcome clinical inertia while also displaying synergistic effects.” The challenging issue of glycemic targets and reconciling them across different guidelines was overviewed by Athena Philis-Tsimikas, MD, Corporate Vice-President of Scripps Research Translational Institute. The session ended with a lively primetime symposium on the management of postprandial glucose control, which included CMHC Chair Anne L. Peters, MD, Irl Hirsch, MD, and Athena Philis-Tsimikas, MD.
Obesity and Lifestyle
Holly R Wyatt, MD, Professor and Vice Chair for Clinical Programs at the University of Alabama Birmingham, discussed challenges and solutions that clinicians face when addressing lifestyle approaches to weight reduction. Dr. Wyatt mentioned that we should be focusing more on weight maintenance than weight loss with our patients, and encouraged clinicians to write “exercise prescriptions” or refer to appropriate specialists. Alice Lichtenstein, D.Sc., Professor of Nutrition Science and Tufts University in Boston, MA, put into perspective the confusing evidence that exists about nutrition and cardiometabolic health and synthesized key messages that every clinician can take back to their practice to address nutrition with their patients—focusing on plant-sourced diets reach in vegetables, fruits, beans, and whole grains. The topics of nutrition and culinary medicine, including practical tips for meal preparation, will also be addressed in depth in the upcoming CMHC masterclass “Nutrition for the cardiometabolic patient: practical strategies to improve outcomes”, which will take place live online on March 4-5 of 2021.
The increasing prevalence of obesity and its manifestation as excess fat in the liver has given rise to a growing epidemic of fatty liver and its more severe form, non-alcoholic steatohepatitis (NASH). In his talk “NASH in a Dash”, Christos Mantzoros, MD, Professor of Medicine at Harvard Medical School, gave an overview of the epidemiology and burden of NASH, current and emerging approaches to evaluation and diagnosis, as well as what can be done now to treat NASH and what we should look forward to the near future as results about the several investigational therapies become available. Dr. Mantzoros invited interested participants to attend the upcoming CMHC masterclass that he is chairing, “Addressing the NAFLD/NASH epidemic: advances in pathophysiology, diagnosis, and management”, taking place live online on January 8-9 of 2021. The rest of the sessions included important talks on the role of metabolic surgery in decreasing overall metabolic risk, the obesity paradox, and how to incorporate and bill for behavioral therapy in obesity management, and the session was concluded with a lively panel discussion with experts Robert H. Eckel, MD, Louis J. Aronne, MD, David E. Cummings, MD, Carl J. Lavie, MD, Alice H. Lichtenstein, D.Sc., Christos S. Mantzoros, MD, DSc, and Holly R. Wyatt, MD.
Conclusion
Developed and led by the foremost clinicians, researchers, and industry thought leaders, the 15th Annual Cardiometabolic Health Congress delivered top-tier clinical perspectives from a myriad of specialties. Designed in direct response to the real-world clinical needs of active cardiometabolic practitioners and patients of all backgrounds, this cutting-edge event disseminated the latest science and clinically equitable strategies in cardiometabolic medicine available. If you are interested in learning more about these challenges, we recommend that you attend the upcoming masterclass, “Who best to stem the cardiometabolic tsunami: cardiology, endocrinology, and primary care,” chaired by Keith C. Ferdinand, MD, which will explore unique issues in the multidisciplinary management of cardiometabolic disease and will be held live online on November 19-20, 2020.
Amanda Jamrogiewicz Cardiometabolic Health Congress 561-997-0112 [email protected]
Artificial Intelligence
IBM, Government of Canada, Government of Quebec Sign Agreements to Strengthen Canada’s Semiconductor Industry
Up to $187M CAD to be invested to progress expansion of chip packaging capacity and capabilities and to strengthen R&D at IBM Canada’s Bromont plant
BROMONT, QC, April 26, 2024 /PRNewswire/ — IBM (NYSE: IBM), the Government of Canada, and the Government of Quebec today announced agreements that will strengthen Canada’s semiconductor industry, and further develop the assembly, testing and packaging (ATP) capabilities for semiconductor modules to be used across a wide range of applications including telecommunications, high performance computing, automotive, aerospace & defence, computer networks, and generative AI, at IBM Canada’s plant in Bromont, Quebec. The agreements reflect a combined investment valued at approximately $187M CAD.
“Today’s announcement is a massive win for Canada and our dynamic tech sector. It will create high-paying jobs, invest in innovation, strengthen supply chains, and help make sure the most advanced technologies are Canadian-made. Semiconductors power the world, and we’re putting Canada at the forefront of that opportunity,” said the Right Honourable Justin Trudeau, Prime Minister of Canada
In addition to the advancement of packaging capabilities, IBM will be conducting R&D to develop methods for scalable manufacturing and other advanced assembly processes to support the packaging of different chip technologies, to further Canada’s role in the North American semiconductor supply chain and expand and anchor Canada’s capabilities in advanced packaging.
The agreements also allow for collaborations with small and medium-sized Canadian-based enterprises with the intent of fostering the development of a semiconductor ecosystem, now and into the future.
“IBM has long been a leader in semiconductor research and development, pioneering breakthroughs to meet tomorrow’s challenges. With the demand for compute surging in the age of AI, advanced packaging and chiplet technology is becoming critical for the acceleration of AI workloads,” said Darío Gil, IBM Senior Vice President and Director of Research. “As one of the largest chip assembly and testing facilities in North America, IBM’s Bromont facility will play a central role in this future. We are proud to be working with the governments of Canada and Quebec toward those goals and to build a stronger and more balanced semiconductor ecosystem in North America and beyond.”
IBM Canada’s Bromont plant is one of North America’s largest chip assembly and testing facilities, having operated in the region for 52 years. Today, the facility transforms advanced semiconductor components into state-of-the-art microelectronic solutions, playing a key role in IBM’s semiconductor R&D leadership alongside IBM’s facilities at the Albany NanoTech Complex and throughout New York’s Hudson Valley. These agreements will help to further establish a corridor of semiconductor innovation from New York to Bromont.
“Advanced packaging is a crucial component of the semiconductor industry, and IBM Canada’s Bromont plant has led the world in this process for decades,” said Deb Pimentel, president of IBM Canada. “Building upon IBM’s 107-year legacy of technology innovation and R&D in Canada, the Canadian semiconductor industry will now become even stronger, allowing for robust supply chains and giving Canadians steady access to even more innovative technologies and products. This announcement represents just one more example of IBM’s leadership and commitment to the country’s technology and business landscape.”
Chip packaging, the process of connecting integrated circuits on a chip or circuit board, has become more complex as electronic devices have shrunk and the components of chips themselves get smaller and smaller. IBM announced the world’s first 2 nanometer chip technology in 2021 and, as the semiconductor industry moves towards new methods of chip construction, advances in packaging will grow in importance.
“Semiconductors are part of our everyday life. They are in our phones, our cars, and our appliances. Through this investment, we are supporting Canadian innovators, creating good jobs, and solidifying Canada’s semiconductor industry to build a stronger economy. Canada is set to play a larger role in the global semiconductor industry thanks to projects like the one we are announcing today. Because, when we invest in semiconductor and quantum technologies, we invest in economic security.” — The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry
“This investment by IBM in Bromont will ensure that Quebec continues to stand out in the field of microelectronics. An increase in production capacity will solidify Quebec’s position in the strategic microelectronics sector in North America.” — The Honourable Pierre Fitzgibbon, Minister of Economy, Innovation and Energy, Minister responsible for Regional Economic Development and Minister responsible for the Metropolis and the Montreal region
About IBMIBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. More than 4,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in semiconductors, AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.
Media ContactLorraine BaldwinIBM [email protected]
Willa HahnIBM [email protected]
Photo – https://mma.prnewswire.com/media/2397908/IBM_Canada_employee_at_the_IBM_Bromont_plant_holding_a_wafer.jpg
Logo – https://mma.prnewswire.com/media/95470/ibm_logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ibm-government-of-canada-government-of-quebec-sign-agreements-to-strengthen-canadas-semiconductor-industry-302128212.html
Artificial Intelligence
HITACHI ACQUIRES MA MICRO AUTOMATION OF GERMANY IN EFFORT TO ACCELERATE GLOBAL EXPANSION OF ROBOTIC SI BUSINESS IN THE MEDICAL AND OTHER FIELDS
HOLLAND, Mich., April 26, 2024 /PRNewswire/ — Hitachi Ltd. (TSE: 6501, “Hitachi”) has signed a stock purchase agreement on April 26 to acquire all shares of MA micro automation GmbH (“MA micro automation”, headquartered in St. Leon-Rot, Germany) from MAX Management GmbH (a subsidiary of MAX Automation SE). MA micro automation is a leading provider of robotic and automation technology (robotic SI) including high-speed linear handling systems, high-precision assembly lines, and high-speed vision inspection technology for Europe, North America, and Southeast Asia, for EUR 71.5M million. The transaction is expected to close in the second half of 2024, pending completion of the customary regulatory filings. After the acquisition is completed, MA micro automation will join JR Automation Technologies, LLC (“JR Automation”), a market leader in providing advanced automation solutions and digital technologies in the robotic system integration business for North America, Europe, and Southeast Asia as a continued effort to expand the company’s global presence.
MA micro automation is a technology leader for automation solutions within micro-assembly. Through its state-of-the-art proprietary high-speed and high-precision automation know-how, combined with unique optical image inspection capabilities, MA micro automation serves high-growth med-tech automation end-markets, covering the production, assembly, and testing medical and optical components including contact lenses, IVD and diabetes diagnostics consumables, and injection molding for medical use. The company was established in 2003 through a carve-out from Siemens*1 and since 2013 has been part of the MAX Automation group.
JR Automation is a leading provider of intelligent automated manufacturing technology solutions, serving customers across the globe in a variety of industries including automotive, life sciences, e-mobility, consumer and industrial products. With over 20 locations between North America, Europe, and Southeast Asia, the leading integrator offers nearly 2 million square feet (185,806 sq. m) of available build and engineering floorspace. This acquisition allows JR Automation to further grow and strengthen both the company’s geographical footprint and their continued commitment on expanding support capabilities within the European region and medical market vertical.
“MA micro automation provides engineering, build and support expertise with established capabilities in complex vision applications, high-speed and high-precision automation technologies. When integrated with JR Automation’s uniform global process and digital technologies, this partnership will further enhance our ability to deliver added value and support to all of our customers worldwide and continue to grow our capabilities in the medical market,” says Dave DeGraaf, CEO of JR Automation. “As we integrate this new dimension, impressive talents and abilities of the MA micro automation team we further enhance our ability to serve our customers, creating a more robust and globally balanced offering.”
With this acquisition, Hitachi aims to further enhance its ability to provide a “Total Seamless Solution*2” to connect manufacturer’s factory floors seamlessly and digitally with their front office data, allowing them to achieve total optimization and bringing Industry 4.0 to life. This “Total Seamless Solution” strategy links organizations’ operational activities such as engineering, supply chain, and purchasing to the plant floor and allows for real time, data-driven decision-making that improves the overall business value for customers.
Kazunobu Morita, Vice President and Executive Officer, CEO of Industrial Digital Business Unit, Hitachi, Ltd. says, “We are very pleased to welcome MA micro automation to the Hitachi Group. The team is based in Europe, providing robotic SI to global medical device manufacturing customers with its high technological capabilities and will join forces with JR Automation and Hitachi Automation to strengthen our global competitiveness. Hitachi aims to enhance its ability to provide value to customers and grow alongside them by leveraging its strengths in both OT, IT, including robotic SI, and “Total Seamless Solution” through Lumada*3’s customer co-creation framework.”
Joachim Hardt, CEO MA micro automation GmbH says, “Following the successful establishment and growth of MA micro automation within the attractive automation market for medical technology products, we are now opening a new chapter. Our partnership with Hitachi will not only strengthen our global competitive position, but we will also benefit from joint technological synergies and a global market presence. We look forward to a synergistic partnership with Hitachi and JR Automation.”
Outline of MA micro automation
Name
MA micro automation GmbH
Head Office
St. Leon-Rot, Germany
Representative
Joachim Hardt (CEO)
Outline of Business
Automation solutions within micro-assembly
Total no. of Employees:
Approx. 200 (As of April 2024)
Founded
2003
Revenues (2023)
€ 46.5 million
Website
*1
“Siemens” is a registered trademark or trademark of Siemens Trademark GmbH & Co. KG in the U.S. and other countries.
*2
“Total Seamless Solution” is a registered trademark of Hitachi, Ltd. in the U.S. and Japan.
*3
Lumada: A collective term for solutions, services and technologies based on Hitachi’s advanced digital technologies for creating value from customers’ data accelerating digital innovation. https://www.hitachi.com/products/it/lumada/global/en/index.html
About JR AutomationEstablished in 1980, JR Automation is a leading provider of intelligent automated manufacturing technology solutions that solve customers’ key operational and productivity challenges. JR Automation serves customers across the globe in a variety of industries, including automotive, life sciences, aerospace, and more.
In 2019, JR Automation was acquired by Hitachi, Ltd. In a strategic effort towards offering a seamless connection between the physical and cyber space for industrial manufacturers and distributers worldwide. With this partnership, JR Automation provides customers a unique, single-source solution for complete integration of their physical assets and data information, offering greater speed, flexibility, and efficiencies towards achieving their Industry 4.0 visions. JR Automation employs over 2,000 people at 21 manufacturing facilities in North America, Europe, and Asia. For more information, please visit www.jrautomation.com.
About Hitachi, Ltd.Hitachi drives Social Innovation Business, creating a sustainable society through the use of data and technology. We solve customers’ and society’s challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products. Hitachi operates under the 3 business sectors of “Digital Systems & Services” – supporting our customers’ digital transformation; “Green Energy & Mobility” – contributing to a decarbonized society through energy and railway systems, and “Connective Industries” – connecting products through digital technology to provide solutions in various industries. Driven by Digital, Green, and Innovation, we aim for growth through co-creation with our customers. The company’s revenues as 3 sectors for fiscal year 2023 (ended March 31, 2024) totaled 8,564.3 billion yen, with 573 consolidated subsidiaries and approximately 270,000 employees worldwide. For more information on Hitachi, please visit the company’s website at https://www.hitachi.com.
Photo – https://mma.prnewswire.com/media/2398552/CENTAURI_IVD_Platform.jpg Logo – https://mma.prnewswire.com/media/2392427/4673549/JR_Automation_and_Hitachi_Combined_Mark_full_color_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/hitachi-acquires-ma-micro-automation-of-germany-in-effort-to-accelerate-global-expansion-of-robotic-si-business-in-the-medical-and-other-fields-302128612.html
Artificial Intelligence
$10 million Artificial Intelligence Mathematical Olympiad Prize appoints further advisory committee members
D. Sculley, Kevin Buzzard, Leo de Moura, Lester Mackey and Peter J. Liu appointed to the advisory committee for the Artificial Intelligence Mathematical Olympiad Prize.
LONDON, April 26, 2024 /PRNewswire/ — XTX Markets’ newly created Artificial Intelligence Mathematical Olympiad Prize (‘AIMO Prize’) is a $10mn challenge fund designed to spur the creation of a publicly shared AI model capable of winning a gold medal in the International Mathematical Olympiad (IMO).
XTX Markets is delighted to announce the appointment of five further advisory committee members. This group brings great expertise in machine learning, including D. Sculley, the CEO of Kaggle; Lester Mackey, a Principal Researcher at Microsoft Research and a Macarthur Fellow; and Peter J. Liu, a research scientist at Google DeepMind.
Prolific mathematicians Kevin Buzzard, who achieved a perfect score in the International Mathematical Olympiad, and Leo De Moura who is the Chief Architect for Lean, the automated reasoning tool, also join the advisory group.
They join the existing advisory committee members Terence Tao and Timothy Gowers, both winners of the Fields Medal, as well as Dan Roberts, Geoff Smith and Po-Shen Loh.
The AIMO Advisory Committee will support the development of the AIMO Prize, including advising on appropriate protocols and technical aspects, and designing the various competitions and prizes.
Simon Coyle, Head of Philanthropy at XTX Markets, commented:
“We are thrilled to complete the AIMO Advisory Committee with the appointments of D., Kevin, Leo, Lester and Peter. Together, they have enormous experience in machine learning and automated reasoning and are already bringing expertise and wisdom to the AIMO Prize. We look forward to announcing the winners of the AIMO’s first Progress Prize soon, and then publicly sharing the AI models to support the open and collaborative development of AI.”
Further information on the AIMO Prize
There will be a grand prize of $5mn for the first publicly shared AI model to enter an AIMO approved competition and perform at a standard equivalent to a gold medal in the IMO. There will also be a series of progress prizes, totalling up to $5mn, for publicly shared AI models that achieve key milestones towards the grand prize.
The first AIMO approved competition opened to participants in April 2024 on the Kaggle competition platform. The first progress prize focuses on problems pitched at junior and high-school level maths competitions. There is a total prize pot of $1.048m for the first progress prize, of which at least $254k will be awarded in July 2024, There will be a presentation of progress held in Bath, England in July 2024, as part of the 65th IMO.
For more information on the AIMO Prize visit: https://aimoprize.com/ or the competition page on Kaggle: https://www.kaggle.com/competitions/ai-mathematical-olympiad-prize/
Advisory Committee member profiles:
D. Sculley
D. is the CEO at Kaggle. Prior to joining Kaggle, he was a director at Google Brain, leading research teams working on robust, responsible, reliable and efficient ML and AI. In his career in ML, he has worked on nearly every aspect of machine learning, and has led both product and research teams including those on some of the most challenging business problems. Some of his well-known work involves ML technical debt, ML education, ML robustness, production-critical ML, and ML for scientific applications such as protein design.
Kevin Buzzard
Kevin a professor of pure mathematics at Imperial College London, specialising in algebraic number theory. As well as his research and teaching, he has a wide range of interests, including being Deputy Head of Pure Mathematics, Co-Director of a CDT and the department’s outreach champion. He is currently focusing on formal proof verification, including being an active participant in the Lean community. From October 2024, he will be leading a project to formalise a 21st century proof of Fermat’s Last Theorem. Before joining Imperial, some 20 years ago, he was a Junior Research Fellow at the University of Cambridge, where he had previously been named ‘Senior Wrangler’ (the highest scoring undergraduate mathematician). He was also a participant in the International Mathematical Olympiad, winning gold with a perfect score in 1987. He has been a visitor at the IAS in Princeton, a visiting lecturer at Harvard, has won several prizes both for research and teaching, and has given lectures all over the world.
Leo de Moura
Leo is a Senior Principal Applied Scientist in the Automated Reasoning Group at AWS. In his spare time, he dedicates himself to serving as the Chief Architect of the Lean FRO, a non-profit organization that he proudly co-founded alongside Sebastian Ullrich. He is also honoured to hold a position on the Board of Directors at the Lean FRO, where he actively contributes to its growth and development. Before joining AWS in 2023, he was a Senior Principal Researcher in the RiSE group at Microsoft Research, where he worked for 17 years starting in 2006. Prior to that, he worked as a Computer Scientist at SRI International. His research areas are automated reasoning, theorem proving, decision procedures, SAT and SMT. He is the main architect of several automated reasoning tools: Lean, Z3, Yices 1.0 and SAL. Leo’s work in automated reasoning has been acknowledged with a series of prestigious awards, including the CAV, Haifa, and Herbrand awards, as well as the Programming Languages Software Award by the ACM. Leo’s work has also been reported in the New York Times and many popular science magazines such as Wired, Quanta, and Nature News.
Lester Mackey
Lester Mackey is a Principal Researcher at Microsoft Research, where he develops machine learning methods, models, and theory for large-scale learning tasks driven by applications from climate forecasting, healthcare, and the social good. Lester moved to Microsoft from Stanford University, where he was an assistant professor of Statistics and, by courtesy, of Computer Science. He earned his PhD in Computer Science and MA in Statistics from UC Berkeley and his BSE in Computer Science from Princeton University. He co-organized the second place team in the Netflix Prize competition for collaborative filtering; won the Prize4Life ALS disease progression prediction challenge; won prizes for temperature and precipitation forecasting in the yearlong real-time Subseasonal Climate Forecast Rodeo; and received best paper, outstanding paper, and best student paper awards from the ACM Conference on Programming Language Design and Implementation, the Conference on Neural Information Processing Systems, and the International Conference on Machine Learning. He is a 2023 MacArthur Fellow, a Fellow of the Institute of Mathematical Statistics, an elected member of the COPSS Leadership Academy, and the recipient of the 2023 Ethel Newbold Prize.
Peter J. Liu
Peter J. Liu is a Research Scientist at Google DeepMind in the San Francisco Bay area, doing machine learning research with a specialisation in language models since 2015 starting in the Google Brain team. He has published and served as area chair in top machine learning and NLP conferences such as ICLR, ICML, NEURIPS, ACL and EMNLP. He also has extensive production experience, including launching the first deep learning model for Gmail Anti-Spam, and using neural network models to detect financial fraud for top banks. He has degrees in Mathematics and Computer Science from the University of Toronto.
About XTX Markets:
XTX Markets is a leading financial technology firm which partners with counterparties, exchanges and e-trading venues globally to provide liquidity in the Equity, FX, Fixed Income and Commodity markets. XTX has over 200 employees based in London, Paris, New York, Mumbai, Yerevan and Singapore. XTX is consistently a top 5 liquidity provider globally in FX (Euromoney 2018-present) and is also the largest European equities (systematic internaliser) liquidity provider (Rosenblatt FY: 2020-2023).
The company’s corporate philanthropy focuses on STEM education and maximum impact giving (alongside an employee matching programme). Since 2017, XTX has donated over £100mn to charities and good causes, establishing it as a major donor in the UK and globally.
In a changing world XTX Markets is at the forefront of making financial markets fairer and more efficient for all.
View original content:https://www.prnewswire.co.uk/news-releases/10-million-artificial-intelligence-mathematical-olympiad-prize-appoints-further-advisory-committee-members-302128542.html
-
Artificial Intelligence3 days ago
9fin grows leadership team with VP Content promotion
-
Artificial Intelligence6 days ago
Aurionpro Solutions acquires Arya.ai, to power next generation Enterprise AI platforms for Financial Institutions
-
Uncategorized4 days ago
US Pushes for AI Partnerships in UAE to Counter China Influence
-
Uncategorized1 day ago
Cherrypicks Partners with AWS DevAx Leading Cloud Technology Innovation for Hong Kong Enterprises
-
Uncategorized3 days ago
Deutsche Telekom: Your Trusted Partner for AI Solutions in Business
-
Artificial Intelligence5 days ago
Dahua Technology Showcases “The Road to a Sustainable Future” at Intertraffic Amsterdam 2024
-
Artificial Intelligence4 days ago
New CPS Protection Platform: TXOne Networks Unveils SageOne at GISec Global
-
Artificial Intelligence4 days ago
Latest Version of Appian Platform Orchestrates Change through AI Process Automation that Moves Business Forward